TY - JOUR T1 - Communicating polygenic and non-genetic risk for atherosclerotic cardiovascular disease - An observational follow-up study JF - medRxiv DO - 10.1101/2020.09.18.20197137 SP - 2020.09.18.20197137 AU - Elisabeth Widén AU - Nella Junna AU - Sanni Ruotsalainen AU - Ida Surakka AU - Nina Mars AU - Pietari Ripatti AU - Juulia J Partanen AU - Johanna Aro AU - Pekka Mustonen AU - Tiinamaija Tuomi AU - Aarno Palotie AU - Veikko Salomaa AU - Jaakko Kaprio AU - Jukka Partanen AU - Kristina Hotakainen AU - Pasi Pöllänen AU - Samuli Ripatti Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/18/2020.09.18.20197137.abstract N2 - Background Algorithms including both traditional risk factors and polygenic risk scores (PRS) can significantly improve prediction of atherosclerotic cardiovascular disease (ASCVD). However, the clinical benefit of adding PRS to clinical risk evaluation remains unclear.Objectives The study evaluated the attitudes of 7,342 individuals (64% women, mean age 56 yrs) upon receiving personal genome-enhanced ASCVD risk information, and prospectively assessed the impact on the participants’ health behavior.Methods The participant’s 10-year risk for ASCVD was estimated using both a traditional clinical risk score and a PRS-enhanced score, and both scores were communicated directly to study participants with an interactive web-tool.Results When reassessed after 1.5 years by a clinical visit and questionnaires, 20.8% of individuals at high (>10%) ASCVD risk had seen a doctor, 12.4% reported weight loss, 14.2% of smokers had quit smoking, and 15.4% had signed up for health coaching online. Altogether, 42.6% of individuals at high risk had made some health behavioral change compared to 33.5% of persons at low/average risk such that a higher baseline risk predicted a favorable change (p<0.001), with both clinical (p<0.001) and genomic factors (p=0.003) contributing independently. Seeing a doctor and weight loss both resulted in clinically significant improvement of lipid profiles (lower LDL-cholesterol and triglycerides) and lower systolic blood pressure (p<0.01).Conclusions Web-based communication of personal ASCVD risk-data including polygenic risk to middle-aged persons can motivate positive changes in health behavior. It supports integration of genomic information into clinical risk calculators as a feasible approach to enhance disease prevention.Condensed Abstract Prediction tools that combine polygenic risk scores (PRS) with clinical factors provide a new opportunity for improved risk assessment and prevention of atherosclerotic cardiovascular disease (ASCVD), but the clinical impact of PRS has hitherto remained unclear. We evaluated the longitudinal effects of using a web-based tool to communicate genome-based ASCVD risk-information to 7,342 middle-aged individuals. 42% of persons at high risk improved their health behavior during follow-up which resulted in clinically significant improvement of lipid profiles and lower systolic blood pressure. This supports integration of PRS into clinical risk calculators as a feasible approach to enhance disease prevention.Competing Interest StatementVS has received honoraria for consulting from Novo Nordisk and Sanofi. He also has ongoing research collaboration with Bayer Ltd. (All unrelated to the present study). PP holds stock in Abomix Oy. The remaining authors have no competing interests to declare.Funding StatementThe GeneRISK study was funded by Business Finland through the Personalized Diagnostics and Care program coordinated by SalWe Ltd (Grant No 3986/31/2013). SamR was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312062), the Finnish Foundation for Cardiovascular Research, the Sigrid Juselius Foundation and University of Helsinki HiLIFE Fellow and Grand Challenge grants. JK was supported by the Academy of Finland Center of Excellence in Complex Disease Genetics (Grant No 312073), the Sigrid Juselius Foundation and University of Helsinki HiLIFE Fellow grant. JJP was supported by the Doctoral Programme in Population Health, University of Helsinki and The Finnish Medical Foundation. Further support for the study was received from the Finnish innovation fund SITRA (EW) and Finska Lakaresallskapet (EW). PR acknowledges support from the Doctoral Programme in Population Health, University of Helsinki.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Ethical Committee of the Helsinki and Uusimaa Hospital district.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe GeneRISK data may be accessed through THL Biobank (https://thl.fi/en/web/thl-biobank). ER -